GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (MEX:TEVA N) » Definitions » EV-to-EBITDA

Teva Pharmaceutical Industries (MEX:TEVA N) EV-to-EBITDA : 21.86 (As of Jun. 30, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Teva Pharmaceutical Industries EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Teva Pharmaceutical Industries's enterprise value is MXN651,080 Mil. Teva Pharmaceutical Industries's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was MXN29,782 Mil. Therefore, Teva Pharmaceutical Industries's EV-to-EBITDA for today is 21.86.

The historical rank and industry rank for Teva Pharmaceutical Industries's EV-to-EBITDA or its related term are showing as below:

MEX:TEVA N' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4041.4   Med: 14.22   Max: 303.42
Current: 23.45

During the past 13 years, the highest EV-to-EBITDA of Teva Pharmaceutical Industries was 303.42. The lowest was -4041.40. And the median was 14.22.

MEX:TEVA N's EV-to-EBITDA is ranked worse than
70.92% of 729 companies
in the Drug Manufacturers industry
Industry Median: 13.83 vs MEX:TEVA N: 23.45

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-30), Teva Pharmaceutical Industries's stock price is MXN317.43. Teva Pharmaceutical Industries's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was MXN-21.499. Therefore, Teva Pharmaceutical Industries's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Teva Pharmaceutical Industries EV-to-EBITDA Historical Data

The historical data trend for Teva Pharmaceutical Industries's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries EV-to-EBITDA Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.04 10.78 -32.84 19.37 54.37

Teva Pharmaceutical Industries Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.13 19.35 25.47 54.37 23.01

Competitive Comparison of Teva Pharmaceutical Industries's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's EV-to-EBITDA falls into.


;
;

Teva Pharmaceutical Industries EV-to-EBITDA Calculation

Teva Pharmaceutical Industries's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=651079.761/29782.143
=21.86

Teva Pharmaceutical Industries's current Enterprise Value is MXN651,080 Mil.
Teva Pharmaceutical Industries's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN29,782 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Teva Pharmaceutical Industries  (MEX:TEVA N) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Teva Pharmaceutical Industries's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=317.43/-21.499
=At Loss

Teva Pharmaceutical Industries's share price for today is MXN317.43.
Teva Pharmaceutical Industries's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-21.499.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Teva Pharmaceutical Industries EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Teva Pharmaceutical Industries Headlines

No Headlines